PRECISION BIOSCIENCES INC Research and Development Expense
PRECISION BIOSCIENCES INC (DTIL) reported Research and Development Expense of $12.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- PRECISION BIOSCIENCES INC research and development expense for the quarter ending 2026-06-30 was $12.39M, a 2.93% decline year-over-year.
- PRECISION BIOSCIENCES INC research and development expense for the quarter ending 2026-03-31 was $13.11M, a 3.52% decline year-over-year.
- PRECISION BIOSCIENCES INC research and development expense for the quarter ending 2025-12-31 was $14.46M, a 9.07% decline year-over-year.
- PRECISION BIOSCIENCES INC research and development expense for the quarter ending 2025-09-30 was $13.35M, a 2.05% increase year-over-year.
- PRECISION BIOSCIENCES INC research and development expense for fiscal 2025 was $54.17M, a 9.04% decline from fiscal 2024.
- PRECISION BIOSCIENCES INC research and development expense for fiscal 2024 was $59.56M, a 11.59% increase from fiscal 2023.
- PRECISION BIOSCIENCES INC research and development expense for fiscal 2023 was $53.38M, a 15.73% increase from fiscal 2022.
- PRECISION BIOSCIENCES INC research and development expense for fiscal 2022 was $46.12M, a 59.98% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $12.39M 10-Q · filed 2026-08-06 | $25.50M 10-Q · filed 2026-08-06 | $39.97M derived: sum of 3 quarters · filed 2026-08-06 | $53.32M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $13.11M 10-Q · filed 2026-05-05 | $27.57M derived: sum of 2 quarters · filed 2026-05-05 | $40.93M derived: sum of 3 quarters · filed 2026-05-05 | $53.69M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $14.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $27.82M derived: sum of 2 quarters · filed 2026-03-12 | $40.58M derived: sum of 3 quarters · filed 2026-08-06 | $54.17M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $13.35M 10-Q · filed 2025-11-03 | $26.12M derived: sum of 2 quarters · filed 2026-08-06 | $39.71M 10-Q · filed 2025-11-03 | $55.62M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $12.77M 10-Q · filed 2026-08-06 | $26.36M 10-Q · filed 2026-08-06 | $42.26M derived: sum of 3 quarters · filed 2026-08-06 | $55.35M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $13.59M 10-Q · filed 2026-05-05 | $29.50M derived: sum of 2 quarters · filed 2026-05-05 | $42.58M derived: sum of 3 quarters · filed 2026-05-05 | $59.80M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $15.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $28.99M derived: sum of 2 quarters · filed 2026-03-12 | $46.22M derived: sum of 3 quarters · filed 2026-03-12 | $59.56M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $13.08M 10-Q · filed 2025-11-03 | $30.31M derived: sum of 2 quarters · filed 2025-11-03 | $43.65M 10-Q · filed 2025-11-03 | $57.04M derived: sum of 4 quarters · filed 2025-11-03 | ||||
| 2024-06-30 | $17.23M 10-Q · filed 2025-08-07 | $30.57M 10-Q · filed 2025-08-07 | $43.96M derived: sum of 3 quarters · filed 2025-08-07 | $59.81M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $13.34M 10-Q · filed 2025-05-15 | $26.73M derived: sum of 2 quarters · filed 2025-05-15 | $42.58M derived: sum of 3 quarters · filed 2025-05-15 | $55.67M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $13.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $29.24M derived: sum of 2 quarters · filed 2025-03-26 | $42.33M derived: sum of 3 quarters · filed 2025-03-26 | $53.38M 10-K · filed 2025-03-26 | ||||
| 2023-09-30 | $15.85M 10-Q · filed 2024-11-04 | $28.94M derived: sum of 2 quarters · filed 2024-11-04 | $39.99M 10-Q · filed 2024-11-04 | $52.67M derived: sum of 4 quarters · filed 2024-11-04 | ||||
| 2023-06-30 | $13.09M 10-Q · filed 2024-08-01 | $21.95M 10-Q · filed 2023-08-04 | $24.14M 10-Q · filed 2024-08-01 | $44.10M 10-Q · filed 2023-08-04 | $36.82M derived: sum of 3 quarters · filed 2024-08-01 | $48.58M derived: sum of 4 quarters · filed 2024-08-01 | ||
| 2023-03-31 | $11.05M 10-Q · filed 2024-05-13 | $22.16M 10-Q · filed 2023-05-09 | $23.73M derived: sum of 2 quarters · filed 2024-05-13 | $35.49M derived: sum of 3 quarters · filed 2024-05-13 | $58.42M derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | $12.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $24.44M derived: sum of 2 quarters · filed 2024-03-27 | $47.38M derived: sum of 3 quarters · filed 2024-03-27 | $46.12M 10-K · filed 2024-03-27 | $83.94M 10-K · filed 2023-03-09 | |||
| 2022-09-30 | $11.76M 10-Q · filed 2023-11-07 | $19.96M 10-Q · filed 2022-11-08 | $34.69M derived: sum of 2 quarters · filed 2023-11-07 | $33.44M 10-Q · filed 2023-11-07 | $62.87M 10-Q · filed 2022-11-08 | $81.14M derived: sum of 4 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $22.94M 10-Q · filed 2023-08-04 | $42.91M 10-Q · filed 2023-08-04 | $69.38M derived: sum of 3 quarters · filed 2023-08-04 | $95.32M derived: sum of 4 quarters · filed 2023-08-04 | ||||
| 2022-03-31 | $19.97M 10-Q · filed 2023-05-09 | $46.44M derived: sum of 2 quarters · filed 2023-05-09 | $72.38M derived: sum of 3 quarters · filed 2023-05-09 | $109.62M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $26.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $52.41M derived: sum of 2 quarters · filed 2023-03-09 | $89.64M derived: sum of 3 quarters · filed 2023-03-09 | $115.24M 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | $25.94M 10-Q · filed 2022-11-08 | $63.17M derived: sum of 2 quarters · filed 2022-11-08 | $88.77M 10-Q · filed 2022-11-08 | $111.89M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $37.23M 10-Q · filed 2022-08-08 | $62.83M 10-Q · filed 2022-08-08 | $85.95M derived: sum of 3 quarters · filed 2022-08-08 | $110.83M derived: sum of 4 quarters · filed 2022-08-08 | ||||
| 2021-03-31 | $25.59M 10-Q · filed 2022-05-09 | $48.72M derived: sum of 2 quarters · filed 2022-05-09 | $73.59M derived: sum of 3 quarters · filed 2022-05-09 | $98.78M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $23.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $48.00M derived: sum of 2 quarters · filed 2022-03-15 | $73.18M derived: sum of 3 quarters · filed 2022-03-15 | $98.06M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | $24.87M 10-Q · filed 2021-11-10 | $50.06M derived: sum of 2 quarters · filed 2021-11-10 | $74.94M 10-Q · filed 2021-11-10 | $94.84M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $25.18M 10-Q · filed 2021-08-12 | $50.06M 10-Q · filed 2021-08-12 | $69.97M derived: sum of 3 quarters · filed 2021-08-12 | $89.76M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $24.88M 10-Q · filed 2021-05-13 | $44.78M derived: sum of 2 quarters · filed 2021-05-13 | $64.57M derived: sum of 3 quarters · filed 2021-05-13 | $87.33M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | $19.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $39.70M derived: sum of 2 quarters · filed 2021-03-18 | $62.45M derived: sum of 3 quarters · filed 2021-03-18 | $82.42M 10-K · filed 2021-03-18 | ||||
| 2019-09-30 | $19.79M 10-Q · filed 2020-11-10 | $42.55M derived: sum of 2 quarters · filed 2020-11-10 | $62.51M 10-Q · filed 2020-11-10 | $78.91M derived: sum of 4 quarters · filed 2020-11-10 | ||||
| 2019-06-30 | $22.76M 10-Q · filed 2020-08-13 | $42.72M 10-Q · filed 2020-08-13 | $59.12M derived: sum of 3 quarters · filed 2020-08-13 | $68.86M derived: sum of 4 quarters · filed 2020-08-13 | ||||
| 2019-03-31 | $19.96M 10-Q · filed 2020-05-15 | $36.36M derived: sum of 2 quarters · filed 2020-05-15 | $46.10M derived: sum of 3 quarters · filed 2020-05-15 | $56.97M derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2018-12-31 | $16.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $26.14M derived: sum of 2 quarters · filed 2020-03-10 | $37.01M derived: sum of 3 quarters · filed 2020-03-10 | $45.12M 10-K · filed 2020-03-10 | ||||
| 2018-09-30 | $9.74M 10-Q · filed 2019-11-12 | $20.61M derived: sum of 2 quarters · filed 2019-11-12 | $28.72M 10-Q · filed 2019-11-12 | |||||
| 2018-06-30 | $10.87M 10-Q · filed 2019-08-14 | $18.99M 10-Q · filed 2019-08-14 | ||||||
| 2018-03-31 | $8.12M 10-Q · filed 2019-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |